multiple sclerosis and semaglutide New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Emerging research suggests that GLP-1

These small organizational habits help ensure safe and consistent medication use throughout your treatment

And because the latter medication works on two different receptors in the body, it may lead to greater weight loss

10.1038/32246 35 LauJ.BlochP.SchfferL.PetterssonI.SpetzlerJ.KofoedJ.et al (2015)

The activation occurs via trans -phosphorylation of two catalytic tyrosines (Y1234 and Y1235) located in the kinase domain, followed by the subsequent auto-phosphorylation of the two docking tyrosines (Y1349 and Y1356) in the C-terminal tail

"Some of the side effects we found, like nausea, are well known, and that shows that the method is picking up a real signal," says Sharath Chandra Guntuku, Research Associate Professor in Computer and Information Science (CIS) at Penn Engineering and the study's senior author